Skip to content

OS Therapies OSTX Share-Based Payment Award Options Outstanding - Number

Share-Based Payment Award Options Outstanding - Number at other companies

CTO
Citius Oncology, Inc.CTOR
18.1M0.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+65.5%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's share-based payment award options outstanding - number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's share-based payment award options outstanding - number?
OS Therapies (OSTX) reported share-based payment award options outstanding - number of 8.4M in Q1 2026.
How has OS Therapies's share-based payment award options outstanding - number changed year-over-year?
OS Therapies's share-based payment award options outstanding - number increased by 191.5% year-over-year, from 2.9M to 8.4M.
What does share-based payment award options outstanding - number mean?
This is the total count of stock options granted to employees and directors that remain unexercised at the reporting date. It reflects the total volume of potential equity claims currently held by the workforce. This metric is a key component in calculating fully diluted share counts.